The latest advice was triggered by the results of a study done in Thailand that showed the AIDS drug tenofovir protected many drug users. Jonathan Mermin, director of AIDS prevention for the Centers for Disease Control and Prevention. The research by the CDC and the Thailand government was published online Wednesday by the journal Lancet.» Read More
*ViiV Healthcare places paediatric abacavir in patent pool. *Move follows earlier sign-up to pool by Gilead Sciences. ViiV Healthcare, majority-owned by GSK, is the second research-based pharmaceutical business to sign up to the new Medicines Patent Pool, following a lead set in 2011 by Gilead Sciences.
Feb 1- Gilead Sciences Inc on Monday reported higher-than- expected quarterly profit and revenue as sales of its flagship HIV drugs beat Wall Street estimates. "They beat handily on the top line and they beat on the bottom line by 2 cents," while suggesting that up to $100 million in sales were due to inventory stock-up, said RBC Capital Markets analyst Michael Yee.